Conformación de los mercados de tierras y estructura agraria en perspectiva comparada. Córdoba y Buenos Aires, 1860-1914

Fil: Banzato, Guillermo. Universidad Nacional de La Plata. Facultad de Humanidades y Ciencias de la Educación. Instituto de Investigaciones en Humanidades y Ciencias Sociales (UNLP-CONICET); Argentina

From biogas to biomethane: A process simulation-based techno-economic comparison of different upgrading technologies in the Italian context

Biogas production and its upgrading to obtain biomethane for use as a transportation fuel has been receiving increasing attention, particularly in Italy. In this work, three commercially developed technologies (Pressure Water Scrubbing, Hot Potassium Carbonate and Pressure Swing Adsorption) are critically compared. Accurate process simulations were carried out to evaluate and optimize the performances in terms of biomethane (and CO2) purity and recovery, as well as specific energy consumption and operating costs, considering a biogas throughput of 500 Nm3 h 121. Results from process simulation were used to develop a detailed Discounted Cash Flow analysis of the different technologies, taking into account the recent subsidies issued on March 19th, 2018 by the Italian legislation to promote biomethane development. All the three processes here considered are able to recover more than 90% of biomethane, with a purity higher than 98%. The economic analysis revealed that, according to the new incentive mechanism set by the Italian so-called Biomethane Government Decree (Government Decree 19/3/2018) the investment payback time would range between 3 and 6 years and the Net Present Value would be positive, whereas in the absence of any incentive the investment would not be profitable for any of these technologies

Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received >= 4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio <3 was associated both with OS and progression-free survival (50.4 vs 8.4 and 20.0 vs 3.3 months). Conclusion: Sunitinib is active and feasible. Patients receiving <4 full-dose cycles or having increased neutrophil-lymphocyte ratio achieved worse outcomes: therefore, these are present potential predictive factors